Drugmakers will conduct lung-cancer trials under single protocol

06/12/2013 | Nature (free content)

A new project aims to create a "master protocol" that will involve multiple pharmaceutical companies using one experimental plan to test multiple lung-cancer treatments in hundreds of clinics throughout the US, speeding up the drug-approval process. The plan will match drugmakers with patients whose tumors are most genetically relevant to the tested treatments. "The drive is to make the whole process of personalized medicine more efficient," said Eric Rubin, vice president of oncology clinical research at Merck. If the project succeeds, it may be applied to additional cancers.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX